A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Clinical trial NCT07035379 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07035379
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2026-09-01
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.